Clinical Scorecard: Second-Generation Anti-VEGF Agents for Neovascular AMD
At a Glance
| Category | Detail |
|---|---|
| Condition | |
| Key Mechanisms | Anti-VEGF therapy targeting vascular endothelial growth factor to improve vision, reduce retinal fluid, and provide longer dosing intervals. |
| Target Population | |
| Care Setting |
Key Highlights
- Second-generation anti-VEGF agents include brolucizumab, faricimab, and aflibercept HD.
- These agents offer extended dosing intervals and improved fluid control compared to first-generation therapies.
- Aflibercept has a higher binding affinity for VEGF-A, enhancing its effectiveness in reducing retinal fluid.
- Vabysmo targets both VEGF-A and Ang-2, potentially improving clinical outcomes.
- Clinical trials demonstrate noninferiority of second-generation agents to Eylea in visual acuity gains, specifically referencing HAWK and HARRIER trials.
Guideline-Based Recommendations
Diagnosis
Management
- Initiate anti-VEGF therapy with agents like brolucizumab, faricimab, or aflibercept HD based on patient needs, specifying dosing regimens.
Monitoring & Follow-up
Risks
Patient & Prescribing Data
Second-generation agents allow for longer intervals between injections, improving patient adherence. Consider patient-specific factors such as fluid burden and previous treatment responses.
Clinical Best Practices
- Utilize OCT and fluorescein angiography to monitor treatment response and adjust dosing intervals accordingly.
References
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.